Arf6 involves Ang II-induced human podocyte injury.

Abstract

A. Human podocytes were treated with 1 μM of angiotensin II (Ang II) for 12, 24 and 48 h, respectively. The levels of Arf6-GTP and total Arf6 were analyzed and compared. GTP-γs and GDP treated samples were used as the positive and negative control, respectively. Data are presented as mean ± SD. n = 3. *p .01 vs. 0 h. B and C. Human podocytes were treated with Ang II for 24 h in the absence or presence of secinH3 (SH3). The non-treated cell was used as the controls (CTL). The levels of Arf6-GTP and total Arf6 were analyzed and compared (B). The effect of 10 μM of secinH3 was evaluated on caspase 3 activity in Ang II-treated podocytes (C). Data are presented as mean ± SD. n = 5. *p .001 vs. CTL, #p .05 vs. Ang II. D. Human podocytes were treated with Ang II for 24 h in the absence or presence of secinH3 (10 μM), losartan (1 μM) and v-ZAD-fmk (10 μM). The vehicle DMSO treated cells were used as the controls (CTL). TUNEL assay was performed for evaluation of apoptotic cell death (arrows). Data are presented as mean ± SD. n = 4. *p .01 vs. CTL, #p .01 vs. Ang II. Magnification x 10. Full length blots of A and B are provided in S2 Fig.</p